---------- Forwarded message --------- From: EquiLend News <clientcommunications@equilend.com> Date: Thu, Oct 17, 2024, 5:54 AM Subject: Orbisa on US 20y Bond To: <G@xny.io> <https://go.equilend.com/e/928823/2024-10-17/j35cc3/842825783/h/q-zAXaVKIijGjauHmK98ejGxUT_BS8ocVeeslQrnVq4> *Orbisa Take Notes on the US 20-Year Bond* As you attended our Bloomberg seminar on Orbisa, you may be interested in more securities lending insights. Today, we bring you our latest analytical piece in the Orbisa Take Notes series, diving into the latest market movements seen in A new focus for Orbisa Take Notes with a focus on fixed income, Orbisa has observed significant securities lending activity for the August 15th 2024 issuance of the United States 20-year bond (4.125% US912810UD80). The US 20y was the second highest revenue generating security in the month of September <https://go.equilend.com/e/928823/ar-to-2-49-billion-in-q3-2024-/j35cc6/842825783/h/q-zAXaVKIijGjauHmK98ejGxUT_BS8ocVeeslQrnVq4> as the US federal reserve moved to cut interest rates by 50 basis points. Orbisa continues to see strong demand for the bond with $5.7 billion of the issuance actively being borrowed, representing nearly 65% of the total supply available to be lent. Click Here to Start Your Free Trial of Orbisa on Bloomberg Today! <https://go.equilend.com/e/928823/screens-apps20orbisa/j35cc9/842825783/h/q-zAXaVKIijGjauHmK98ejGxUT_BS8ocVeeslQrnVq4> [image: Orbisa Take Notes on the US 20-Year Bond] <https://go.equilend.com/e/928823/tm-campaign-TakeNotes-20Y-Bond/j35ccd/842825783/h/q-zAXaVKIijGjauHmK98ejGxUT_BS8ocVeeslQrnVq4> Click Here to Dive into Orbisa Take Notes on the US 20-Year Bond <https://go.equilend.com/e/928823/tm-campaign-TakeNotes-20Y-Bond/j35ccd/842825783/h/q-zAXaVKIijGjauHmK98ejGxUT_BS8ocVeeslQrnVq4> Orbisa (the “Firm”) is not registered as an investment advisor or otherwise in any capacity with any securities regulatory authority. The information contained, referenced or linked to herein is proprietary and exclusive to the Firm, does not constitute investment or trading advice, is provided for general information and discussion purposes only and may not be copied or redistributed without the Firm’s prior written consent. The Firm assumes no responsibility or liability for the unauthorized use of any information contained, referenced or linked to herein. © 2024 EquiLend Holdings LLC. All rights reserved. Unsubscribe <https://go.equilend.com/unsubscribe/u/928823/79c841ab5e11a0b553270517f6f862e6d3177d2ee57b800725ab67b161265fd0/842825783>